Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CoLig-10
- Development stage
- Unknown
- Lead developer
- Tetra Corporation
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Administration
- Oral
01
Overview
CoLig-10 is a multi-ingredient dietary supplement developed by Tetra Corporation to support joint health and nourish connective tissues. The formulation includes structural components such as collagen and hyaluronic acid, which are essential for the integrity of ligaments, tendons, and cartilage. It also incorporates a suite of antioxidants, including resveratrol, grape seed extract, green tea extract, and alpha-lipoic acid, along with specific vitamins and amino acids that facilitate collagen synthesis. CoLig-10 is indicated for the relief of joint pain, stiffness, swelling, and arch pain, and is typically distributed through healthcare providers.
- Brand names
- CoLig-10CoLig10CoLig 10
Beyond the preview
Go deeper on CoLig-10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoLig-10.